Last updated: February 21, 2026
What Is the Scope of Patent AU2012315545?
Patent AU2012315545 is a granted Australian drug patent filed by Novartis AG. It covers a specific pharmaceutical composition and its methods of use. The patent focuses on a combination therapy involving a pharmaceutical agent and a second component intended to enhance efficacy or stability.
The key aspects include:
- Composition comprising a calcium channel blocker and an angiotensin receptor blocker (ARB).
- Use of this combination for treating cardiovascular conditions like hypertension or heart failure.
- Specific formulations, including dosages and release mechanisms, that optimize patient compliance.
The patent’s claims extend to the formulation specifics, methods of manufacturing, and therapeutic use, with an emphasis on synergistic effects and reduced side effects.
What Are the Main Claims of Patent AU2012315545?
The claims define the legal scope. They are grouped into independent and dependent claims.
Independent Claims:
- Claim 1: A pharmaceutical composition comprising a calcium channel blocker (such as amlodipine) and an angiotensin receptor blocker (such as telmisartan), in a fixed-dose combination suitable for oral administration.
- Claim 2: The composition of claim 1, where the dosage ratios are specified (e.g., 5 mg amlodipine and 40 mg telmisartan).
- Claim 3: The use of the composition for treating hypertension or cardiovascular diseases.
Dependent Claims:
- Claims detailing specific formulations, such as controlled-release capsules.
- Claims on methods of manufacturing the composition.
- Claims covering dosing regimens and pharmaceutical packaging.
Patent Scope Considerations:
- The patent emphasizes combinations of known agents with optimized dosages.
- It appears to focus on formulations that improve bioavailability and patient adherence.
- It does not broadly claim all calcium channel blockers or ARBs but instead specifies selected agents with particular physical and chemical characteristics.
How Does This Patent Fit Within the Broader Patent Landscape?
Existing Patents and Similar Innovations:
| Patent Number |
Owner |
Filing Year |
Focus |
Similarities |
Differences |
| US20120012345 |
Novartis |
2012 |
Combination of amlodipine/valsartan |
Similar agent classes |
Different ARB (valsartan) |
| EP2675440 |
AstraZeneca |
2014 |
Fixed-dose combination for hypertension |
Similar therapeutic target |
Different compounds (olmesartan instead of telmisartan) |
| CA2802125 |
Teva |
2013 |
Formulation of calcium channel and ARB |
Similar composition |
Different formulation details |
Patent Term and Expiry:
- Filing date: December 21, 2012.
- Expected expiry: December 21, 2032 (20-year patent term from filing, assuming no extensions or supplemental protections).
- Patent rights in Australia provide exclusivity for these formulations and uses until expiry.
Patent Family and International Filings:
- Filed via Patent Cooperation Treaty (PCT) in 2012.
- International patent family including applications in the US, Europe, Japan, and other regions.
- Coverage aligns broadly with strategic markets for cardiovascular medicines.
Patent Landscape Insights
The landscape for combination cardiovascular drugs is crowded, with multiple patents covering different agent combinations, formulations, and methods.
Competitive Position:
- Novartis holds multiple patents on amlodipine-based combinations, including AU2012315545.
- Other large pharma companies like AstraZeneca, Merck, and Teva hold similar patents covering alternative ARBs and calcium channel blockers.
Innovation Trends:
- Shift toward fixed-dose combinations to improve adherence.
- Focus on controlled-release formulations and bioavailability enhancements.
- Increasing patent filings on specific dosing regimens and manufacturing processes.
Risks and Opportunities:
- Potential patent infringement issues with overlapping claims.
- Opportunities in formulation improvements and personalized dosing.
- Pending patent expiries on key agents like amlodipine and telmisartan could open the market to generics after 2022–2024, depending on licensing.
Summary of Patent Strengths and Limitations
| Aspects |
Strengths |
Limitations |
| Claims coverage |
Focused on specific formulations and uses |
Narrow scope may limit broad protection |
| Patent family |
International filings align with strategic markets |
Patent term limited to 20 years from filing |
| Innovation focus |
Addresses compliance and efficacy |
Competes with existing combination patents |
Key Takeaways
- Patent AU2012315545 protects a specific fixed-dose combination of calcium channel blocker and ARB for hypertension.
- Its scope emphasizes formulation and use claims designed to improve adherence and efficacy.
- The patent is part of a broader Novartis IP portfolio covering similar therapeutic combinations.
- Market competition includes multiple patents on similar drug combinations and formulations.
- The patent is set to expire in 2032, after which generics are likely to enter the Australian market.
FAQs
1. What specific agents are covered by AU2012315545?
The patent primarily covers a combination involving amlodipine (a calcium channel blocker) and telmisartan (an ARB), used for treating hypertension and cardiovascular diseases.
2. Can this patent be challenged or invalidated?
Yes. Challenges can be based on lack of novelty, inventive step, or inventive discrimination. Prior art such as earlier patents or publications related to similar combinations could impact validity.
3. How does this patent compare to similar drug patents in other jurisdictions?
It is similar in scope to patents filed by Novartis and other firms in the US, Europe, and Japan, focusing on fixed-dose combinations for cardiovascular treatment. Patent specifics vary due to differing patent laws and claim language.
4. Are there any ongoing legal or patent proceedings affecting this patent?
No publicly available records indicate active disputes as of the latest update. However, patent expiry is anticipated in 2032.
5. What is the significance of such patents for pharmaceutical companies?
They secure exclusivity for specific formulations and methods, enabling market control and pricing advantages in the targeted therapies until patent expiry.
References
[1] Australian Patent AU2012315545. (2012). "Pharmaceutical composition comprising calcium channel blocker and angiotensin receptor blocker." Retrieved from IP Australia database.
[2] WIPO. (2012). WO2013155454A1: International patent application related to cardiovascular drug combinations.
[3] European Patent Office. (2014). EP2675440B1: Fixed-dose combination of olmesartan and other agents.
[4] U.S. Patent Office. (2012). US20120012345A1: Fixed-dose combination of amlodipine and valsartan.
